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INTRODUCTION
Microvascular flap surgery is a reliable method for recon-
structive surgery. Preconditions for success are thoughtful
patient assessment, flawless surgical technique, and eligible
perioperative care.
Post-lesion damage of endothelial cells employs its proco-
agulant moiety combined with other factors of the classical
Virchow (1845) triad. A hypercoagulable state is an obvious
predictor for thrombosis in particular groups of patients,
e.g., trauma, malignancy, etc. (Biben and Atmodiwirjo,
2019; Vanags et al., 2020).
Regarding inherited thrombophilia, the majority of single
nucleotide polymorphisms (SNPs) are associated with de-
fects affecting anticoagulant mechanisms (Dählback, 2008).
Recent evidence suggests that five SNPs (Table 1) might in-
fluence thrombosis advancement: rs6025 in the Factor V
Leiden (FVL) gene, rs1799963 in the Factor II (FII) gene,
rs2066865 in the Fibrinogen Gamma Chain (FGG) gene,
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Microvascular flap surgery is a reliable method for reconstructive surgery. To avoid and foresee
free flap thrombosis advancement after microvascular flap surgery, patient assessment, flawless
surgical technique, and eligible perioperative care are pivotal. In this prospective observational
study, we aimed to elucidate the most common inherited single nucleotide polymorphisms (SNPs)
attributable to free flap thrombosis. A total of 152 patients undergoing microvascular flap surgery
during the study period of 2016–2019 were analysed for five SNPs: rs6025 in Factor V Leiden
(FVL) gene, rs1799963 in Factor II (FII) gene, rs2066865 in Fibrinogen Gamma Chain gene
(FGG), rs2227589 in SERPINC 1 gene and rs1801133 in Methylene Tetrahydrofolate Reductase
(MTHFR) gene. Activated protein C resistance (aPCR), prothrombin, antithrombin (AT), fibrinogen
and homocysteine plasma levels were measured to determine association with the analysed
SNPs and with free flap thrombosis advancement. Our preliminary results show that carriers of
FVL mutation were associated with aPCR, as we observed significantly lower aPCR plasma lev-
els in carriers of genotype C/T, as compared to C/C; p = 0.006 (CI 95%, 0.44 to 1.19). Addi-
tionally, mean fibrinogen plasma levels were higher in carriers of FGC gene rs2066865 genotype
A/A (5.6 ± 1.81 g/l), as compared to G/A and G/G; p = 0.04 (CI 95%, 0.007 to 1.09); p = 0.004
(CI 95%, 0.48 to 2.49), respectively. The study group included 12 patients (7.9%) with free flap
thrombosis. For one patient free flap thrombosis advancement might have been related to the
rs6025T – FVL mutation with a PCR plasma level 1.21. Lower aPCR levels was associated with
carriers of FVL rs6025 C/T and higher fibrinogen plasma levels with carriers of FGG rs2066865
A/A, suggesting that these genotypes might predict higher free flap thrombosis risk, but we found
no significant association between analysed SNPs and free flap thrombosis advancement.
Key words: polymorphisms, free flap thrombosis, Leiden factor, hyperhomocisteinemia, anti-
thrombin deficiency, fibrinogen, prothrombin gene mutation.
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rs2227589 in the SERPINC1 gene and rs1801133 in the
Methylene Tetrahydrofolate Reductase (MTHFR) gene
(Rees et al., 1995; El-Galaly et al., 2013; Pathare et al.,
2004). However, there is not much literature demonstrating
associations of mentioned SNPs and occurrence of free flap
thrombosis in microvascular flap surgery patients.
Therefore, the aim of our study was to analyse the most
common inherited SNPs that might have an effect on free
flap thrombosis advancement after microvascular flap sur-
gery.
Factor V Leiden gene, a mutation of FVL, is the most
widespread autosomal dominant genetic mutation (Rees et
al., 1995; Rosendaal et al., 1995; Ridker et al., 1997). FVL
mutation is a missense mutation in the FV gene
(NM_000130.4(F5):c.1601G>A (p.Arg534Gln), rs6025
(c.1691C>T) where in position R506 arginine is replaced by
glutamine (Zoller and Dahlbäck, 1994; Friedman et al.,
2010). It is known as activated protein C resistance (aPCR),
which is attributable to the FVL mutation in up to 95% of
cases (Segers, 2007).
Factor II gene. FII or the prothrombin mutation
(NM_000506.4(F2):c.97 G>A, rs1799963 G/A), was found
to occur in 3–17 % of patients with VTE and about 1–8 %
of healthy controls (Rosendaal et al., 1998). Carriers of the
rs1799963A allele have a higher plasma prot hrombin
level and 2.8-fold higher risk of VTE (Poort et al., 1996;
Meltzer et al., 2010).
Fibrinogen gamma chain gene. Fibrinogen is a plasma
glycoprotein synthesised by hepatocytes. Fibrinogen mole-
cules are comprised of two sets of three polypeptide chains
— A alpha; B beta; and gamma (Henschen et al., 1983).
The three chains are encoded by three separate genes, fi-
brinogen alpha (FG>A), fibrinogen beta (FGB), and fibrino-
gen gamma (FGG). The rare allele T of rs20066865 poly-
morphism (NM_000509.5(FGG):c.216 GA, rs2066865G/A)
in the FGG gene is described as a reason for alterations in
the coagulation system (Drizlionoka et al., 2019).
A polymorphism in SERPINC1 gene
(NM_000488.3(SERPINC1):c.41+141C>T, rs2227589 C/T)
is recognised as causing antithrombin (AT) deficiency and
is associated with the highest risk of VTE of all known in-
herited thrombophilias. Inherited AT deficiency is an
uncommon autosomal dominant disorder. Prevalence in
general population is 1 : 2000 to 1 : 5000 and is associated
with a 10-fold to 20-fold increased risk of VTE (Patnaik
and Moll, 2008). Most of the VTE episodes are unpro-
voked for those with AT deficiency (Patnaik and Moll,
2008).
Methylene Tetrahydrofolate Reductase gene, a polymor-
phism in MTHFR gene (NM_005957.4(MTHFR):c.665
G>A (p.Ala222Val), results in reduced activity of this en-
zyme (Rosenberg et al., 2002). An increased level of homo-
cysteine has been reported as a risk factor for coronary ar-
tery disease (Rozen, 1997; Stanger et al., 2004), especially
in young/middle aged Caucasians with an increased risk for
myocardial infarction (Xuan et al., 2011), cerebral and pe-
ripheral artery disease (Welsch et al., 1997).
MATERIALS AND METHODS
Subject and perioperative management. In an observa-
tional prospective case series study, we enrolled 152 adult
consecutive patients who had microvascular flap surgery in
the Centre of Plastic and Reconstructive Microsurgery of
Latvia during 2016–2019.
All patients undergoing microvascular flap surgery were en-
rolled during the study period after exclusion criteria were
applied. The informed consent form including the request to
donate genetic material and the protocol was approved by
the Latvian Central Ethics Committee (No. 1/28-11-16). All
patients provided written, informed consent.
The exclusion criteria were: pregnancy, peripartum period;
transfusion of allogeneic blood components, and/or coagu-
lation factors within 72 h perioperatively, proven left ven-
tricular failure, allogenic bone marrow transplantation, liver
failure, liver transplantation, and end-stage kidney disease.
General anaesthesia (GA) was provided for all patients ac-
cording to the guidelines for free flap transfer microsurgery.
Peripheral nerve blocks under ultrasound guidance were
performed for analgesia requirement when applicable. For
those without a peripheral nerve block, continuous intrave-
nous infusion of fentanyl 0.5–1 mcg/kg/h was administered.
Fluid management, oxygen supply and transfusion manage-
Table 1. Relationship between analysed SNPs, coded plasma proteins and effect on coagulation
SNP Gene Plasma proteins Effect on coagulation
rs6025 FVL aPCR Leads to aPCR and inactivation of factor Va by aPC
rs1799963 FII Thrombin Leads to elevated prothrombin levels and an increase of production of thrombin and thrombin
activable fibrinolysis inhibitor
rs2066865 FGG Fibrinogen Leads to increase in plasma fibrinogen concentration
rs2227589 SERPINC1 AT Leads to AT deficiency with increase in thrombin and factor Xa activity
rs1801133 MTHFR Homocysteine Leads to reduced activity of the MTHFR enzyme and increased plasma homocysteine level,
promoting inflammation and atherosclerosis
SNP, single nucleotide polymorphism; FVL, Factor V Leiden; FII, Factor II; FGG, Fibrinogen Gamma; MTHFR, methylene tetrahydrofolate reductase; AT,
antithrombin; aPCR, activated protein C resistance; aPC, activated protein C
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ment were provided in the post-anaesthesia care unit with
tight haemodynamic monitoring and followed local guide-
lines for microvascular flap surgery post-operative care.
During the study, a total of 152 microvascular flap surgeries
were performed by highly trained specialists. The venue of
free flap thrombosis (i.e., arterial, venous, or both) was as-
sured by direct visualisation during the revision of anasto-
mosis.
For patients on direct oral anticoagulants, medication was
stopped 72 h prior to sample collection to avoid any inaccu-
racy in testing. For patients taking a vitamin K antagonist,
medication was stopped according to the patient’s interna-
tional normalised ratio (INR) level, 4 to 5 d prior to sample
collection. Patients with a high thrombosis risk were
switched to low-molecular-weight heparin (LMWH) and
use was discontinued 12 h prior to the surgery.
Each patient was genotyped to determined SNPs: rs6025 in
the FVL gene, rs1799963 in the FII gene, rs2066865 in the
FGG gene, rs2227589 in the SERPINC1 gene and
rs1801133 in the MTHFR gene. Plasma concentrations of
aPCR, prothrombin, fibrinogen, AT and serum homocys-
teine were measured one time pre-operatively.
Laboratory workup and genotyping. Blood samples were
drawn on the day of microsurgery prior to the induction of
GA and any crystalloid infusion. All tests were processed
within an hour.
To determine potential alteration in plasma protein levels
associated with the analysed SNPs, the following laboratory
measurements were performed: aPCR was measured using
the clotting method with a Sysmex CS2100i, UK LTD (ref-
erence range  1.8). Prothrombin was measured using the
clotting time method (for prothrombin added tissue
thromboplastin ISI < 1.5) with a Sysmex system, CS-2100i,
UK LTD (reference range 70–130%). Plasma AT was mea-
sured using a chromogenic method with a Sysmex
CS-2100i, UK LTD (reference range 75–125%). Total
plasma fibrinogen concentration was measured by Clauss
method in citrated plasma using a STA-R COMPACT
Diagnostika Stago, Asnières-sur-Seine, France (reference
range 2–4 g/l). Homocysteine was measured using the im-
munochemical luminescence method on a ADVIA, Cen-
taur, Siemens Healthcare GmbH, Germany (reference range
5.00–12.00 mkmol/l).
Genomic DNA was extracted using the standard phenol-
chloroform extraction protocol. Extracted DNA was dis-
solved in water. Genotyping was performed by Taqman
Pre-Designed SNP Genotyping Assays (Applied Biosys-
tems, Foster City, California, USA) on a Viia7 Real-Time
polymerase chain reaction (PCR) system (Applied Biosys-
tems) (Livak, 1999) according to the supplier’s recommen-
dations.
In addition to genetic and coagulation laboratory workout,
patients were interviewed to register co-morbidities, par-
ticularly focusing on previous thrombotic events. We also
registered demographic data, localisation of soft tissue de-
fect, type of free flap transfer and the duration of surgery.
Statistical analysis. We compared variables with inde-
pendent-sample (unpaired) t-tests using SPSS 23 Statistics
software (IBM Korea, Seoul, Korea). The Kolmogorov–
Smirnov test was used to check whether the variables fol-
lowed a normal distribution. Normally distributed, continu-
ous variables were presented as means ± standard deviation
(M ± SD) and categorical variables as percentages (%). The
frequency of alleles was tested against Hardy–Weinberg
equilibrium. Odds ratios and 95% confidence intervals were
calculated to evaluate factor impacts between groups. Com-
parisons between genotype groups were performed with
Kruskal–Wallis H tests for nonparametric variables and
with ANOVA for parametric variables. Pearson’s and two-
tailed Fisher exact tests were used for data comparison, de-
pending on the number of cases. The Spearman’s rank cor-
relation coefficient was used where applicable. Statistical
significance was assumed as two-tailed with p < 0.05.
RESULTS
We analysed 152 patients scheduled for microvascular flap
surgery (35 female and 117 males), who met the inclusion
criteria. Table 2 displays demographic and clinical variables
of the studied group. History of personal or family thrombo-
sis was observed in 5.2% and 13.8% of female and male
cases, respectively. Most patients had surgery after more
than 30 days post-traumatic injury and defect localisation
was mostly on a lower extremity. Correlation was not ob-
served between SNPs and metabolic disturbances and
smoking.
Relationships between SNPs and coded protein plasma
levels. To analyse each SNP, patients were classified by
their FVL gene C/T, FII gene G/A, FGG gene G/A,
SERPINCI1 gene C/T and MTHFR gene G/A characteristics
and subdivided into three groups, according to the genotype
of each gene polymorphism. The genotype results of ana-
lysed SNPs were all in Hardy-Weinberg equilibrium. Table
3 shows protein plasma levels in relation to the analysed
SNPs.
rs6025 FVL gene. 96% of the studied population had the
C/C genotype of the FVL gene rs6025 polymorphism. We
observed significantly a lower aPCR plasma level in carri-
ers of genotype C/T, as compared to C/C; p = 0.006 (CI
95%, 0.44 to 1.19). None of the analysed patients had
genotype T/T.
rs2066865 FGG gene. Analysis of the association between
FGG gene rs2066865 polymorphism and fibrinogen plasma
levels showed that mean fibrinogen plasma levels were
higher in carriers of the genotype A/A, compared to G/A
and G/G; p = 0.04 (CI 95%, 0.007 to 1.09); p = 0.004 (CI
95%, 0.48 to 2.49), respectively. The largest number of pa-
tients were carriers of G/G and A/G genotypes (in 60% and
34% of cases) and only 6% of the studied patients had the
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A/A genotype, which was associated with a significantly
higher mean fibrinogen plasma level (5.6 ± 1.81 g/l).
rs2227589 SERPINC1 gene. Although carriers with the
C/C genotype (81%) of the SERPINC1 gene rs2227589
polymorphism had a tendency to have a lower AT plasma
level, we did not observe a significant difference of AT
plasma level between homo- and heterozygous allele carri-
ers; p = 0.09 (CI 95%, 1.37 to 18.02).
rs1799963A in FII gene. As for the above gene, mean
prothrombin plasma level displayed no significant differ-
ence between FII gene rs1799963A polymorphism geno-
type groups; p = 0.8 (CI 95%, 20.31 to 26.23 between G/G
and G/A genotype carriers).
rs1801133 MTHFR gene. Carriers of the MTHFR gene
rs1801133 genotype G/A and A/A presented with slightly
higher plasma levels of homocysteine, as compared with
carriers of genotype G/G, but this difference did not reach
significance; p = 0.07 (CI 95%, 0.26 to 5.6) between G/G
and G/A; p = 0.26 (CI 95%, 2.39 to 8.26) between G/G and
A/A.
Case series. In Table 4, we demonstrate data for 12 patients
(7.89%) of 152 who presented with free flap thrombosis.
Only one of the twelve patients had all wild type alleles of
analysed SNPs. The other eleven had one or a combination
of two of the analysed SNPs. Polymorphism rs1801133 in
the MTHFR gene G/A genotype was most often observed in
combination or alone (Table 4). For all of those patients, the
homocysteine plasma level was higher than normal, with a
mean value 13.3 ± 0.74 mKmol/l. Two patients had solely a
in MTHFR gene. One presented with free flap thrombosis in
arterial and the other in venous flow. The rs2066865 poly-
morphism in the FGG gene G/A genotype was most often
detected, and associated with a higher mean fibrinogen
plasma level (4.7 ± 0.35 g/l). Only one patient had a homo-
zygote form of A/A genotype, with a fibrinogen plasma
level of 4.7 g/l. None, except one, had perioperative throm-
boprophylaxis. Most of the patients (10 of 12, 83%) with
free flap thrombosis had a defect with localisation on a
lower extremity.
The first patient in Table 4 was a carrier of the FVL gene
rs6025 polymorphism C/T genotype who presented with a
markedly lower aPCR plasma level (1.21) and underwent
microvascular flap surgery twice in two years. Both of these
transfers were complicated by free flap thrombosis. Free
flap thrombosis might have been related to the rs6025T
FVL mutation in this case.
When comparing patients with (n = 12) and without (n =
140) free flap thrombosis, we were not able to find any spe-
cific factor or their combinations that independently af-
fected advancement of free flap thrombosis.
DISCUSSION
In this observational case series study we evaluated the as-
sociation of hereditary thrombophilia with free flap throm-
bosis advancement in microvascular flap surgery. We fo-
Table 2. Characteristics of the studied group
n = 152 n (%)
Age, years (mean ± SD) 45.1 (14.9)
Sex, female 35 (23)
History of thrombosis 10 (5.2)
Family history of thrombosis 21(13.8)
Smoking 64 (42.1)


























Data are presented as mean ± SD or number (n) and percentage (%).
*Diabetes mellitus; adiposities (BMI > 25)
Table 3. Determined SNPs and coded protein plasma levels
Type of SNP Coded protein plasma levels,
normal range (min.-max.)
p
rs6025 FVL (C > T) aPCR (>1.8)
C/C (n = 146)
C/T (n = 6)





rs1799963 FII (G > A) Prothrombin (70–130%)
G/G (n = 148)
G/A (n = 3)





rs2066865 FGG (G > A) Fibrinogen (2–4 g/l)
G/G (n = 91)
G/A (n = 52)
A/A (n = 9)
4.1 ± 1.3 #
4.6 ± 1.7*
5.6 ± 1.8 *#
* 0.04
# 0.004
rs2227589 SERPINC1 (C > T) AT (75–125%)
C/C (n = 123)
C/T (n = 28)





rs1801133 MTHFR (G > A) Homocysteine (5.00–12.00
mkmol/lL)
G/G (n = 81)
G/A (n = 61)





Values are presented as mean, ± SD; sig. 2- tailed p < 0.05. SNP, single
nucleotide polymorphism; FVL, Factor V Leiden; FII, Factor II; FGG,
Fibrinogen Gamma; MTHFR, methylene tetrahydrofolate reductase; AT,
antithrombin; aPCR, activated protein C resistance; NS, nonsignificant; n,
number; G, guanine; A , adenine; T, thymine; C, cytosine
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cused on five SNPs, which were mentioned in literature
most frequently in relation with their coded plasma protein
levels and free flap thrombosis advancement of diverse lo-
calisation, either venous or arterial origin, in 152 microvas-
cular flap surgery patients. Our study group was relatively
young (mean age 45.1 years), and only 5.2 per cent had a
history of previous thrombotic events and 13.8 per cent had
a positive family history of thrombosis. This study revealed
that a significantly lower aPCR plasma level occurred in
carriers of FVL gene genotype C/T in the analysed polymor-
phism. We also noticed a highest fibrinogen plasma level in
carriers of FGG gene genotype A/A in the analysed poly-
morphism. Correspondingly, for one patient, advancement
of free flap thrombosis was most likely associated with one
of our analysed SNP where aPCR was detected.
In microvascular flap surgery both arterial and venous cir-
culation systems are involved. Therefore, there is still lack
of a haemostatic tool that would allow evaluating who
would benefit from perioperative thromboprophylaxis with-
out increasing risk of haemorrhage. Although has not yet
been evaluated for microvascular flap surgery, the 2005 Ca-
prini Risk Assessment Model could be applicable for those
patients (Pannuci et al., 2015).
It has been mentioned that approximately 5 per cent of
aPCR could occur by different mechanisms (Segers, 2007),
particulary in FVL gene rs6025T C/T genotype carriers. We
recognised only one patient with aPCR who had a C/T ge-
notype combined with a markedly lower aPCR plasma level
and who underwent microvascular flap surgery twice in two
years’ time period, both with eventual free flap thrombosis.
aPCR can be detected in 20% of patients wih VTE and in
more than a half of selected families with thrombophilia
(Rees et al.,1995; Rosendaal et al., 1995). The prevalence
of the homozygous T/T genotype form is 1.5 per cent of the
general population (Rees et al., 1995). Thus, we can explain
why none of the patients in our study group had this geno-
type of the FVL gene for the analysed SNP.
None of our patients with a mutation in the FII gene had
free flap thrombosis. All patients had prothrombin plasma
levels within the normal range. It has been observed that
when the prothrombin cut off value reached 95.19%, risk of
thrombosis increased by 2.34 times (Drizlionoka et al.,
2019). This is consistent with observations made by pre-
vious investigators. Patients with a prothrombin plasma
level higher than 1.15 U/ml had a 2.1-fold higher risk of
VTE than those in the reference category < 0.95 U/ml
(Poort et al., 1996).
We believe that increased risk of free flap thrombosis might
be associated with increased plasma levels of fibrinogen.
Carriers of the FGG gene rs2066865 genotype A/A had sig-
Table 4. Case series of patients with free flap thrombosis
Free flap transfer Cause Defect localisation Thrombosis venue SNP and genotype Laboratory parameters
Scapular/
Parascapular
osteomyelitis lower extremity venous * rs6025 FVL C/T
rs2066865 in FGG G/A
aPCR 1.21
Fibrinogen 4.24 g/l
Medial plantar artery osteomyelitis lower extremity arterial rs2227589 in SERPINC1 C/T
rs1801133 in MTHFR G/A
AT 76%
Homocysteine 13.3 mkmol/l
Lateral arm trauma lower extremity venous rs2066865 in FGG G/A Fibrinogen 4.4 g/l
Scapular/
Parascapular
osteomyelitis lower extremity venous rs1801133 in MTHFR G/A Homocysteine 12.8 mkmol/l
Scapular/
Parascapular
polytrauma lower extremity venous rs2066865 in FGG G/A Fibrinogen 4.7 g/l
Serratus
anterior muscle
trauma lower extremity arterial
and venous
rs2066865 in FGG G/A
rs2227589 in SERPINC1 C/T
rs1801133 in MTHFR G/A
Fibrinogen 5.1 g/l
Osteocutaneus trauma lower extremity arterial
and venous
rs2227589 in SERPINC1 C/T
rs1801133 in MTHFR G/A
AT 81%
Homocysteine 14.1 mkmol/l
Osteocutaneus osteomyelitis lower extremity arterial
and venous
rs2066865 in FGG G/A
rs1801133 in MTHFR G/A




osteomyelitis lower extremity arterial
and venous
rs2227589 in SERPINC1 C/T AT 111.8%
Radial forearm malignancy orofacial arterial rs1801133 in MTHFR G/A Homocysteine 12.2 mkmol/l
Lateral arm trauma upper extremity venous rs2066865 in FGG A/A





trauma lower extremity venous - no alteration in laboratory data
SNP, single nucleotide polymorphism; FVL, Factor V Leiden; FII, Factor II; FGG, Fibrinogen Gamma; MTHFR, methylene tetrahydrofolate reductase; AT,
antithrombin; aPCR, activated protein C resistance; NS, nonsignificant; n, number; G, guanine; A, adenine; T, thymine; C, cytosine; * patient with noticed as-
sociation between SNP rs6025 in FVL and aPCR and free flap thrombosis
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nificantly higher levels of fibrinogen, compared with carri-
ers of genotype G/G. We also noticed that plasma levels of
fibrinogen are higher for FGG gene heterozygotes A/G. The
latter genotype was found in 5 of 12 patients with free flap
thrombosis, as shown in Table 4. Undas and Casini (2019)
previously reported that patients with hereditary dysfibrino-
genemia are highly heterogeneous in clinical manifestation.
Correlations between genotype and phenotype may some-
times not be established, mainly due to involvement and
overlapping of a variety of mechanisms like changes in fi-
brin network stability, strength, architecture and impairment
in fibrinogen binding sites, resulting in qualitative and
quantitative alteration. Therefore, we speculate that A/G ge-
notype carriers with consequently higher plasma fibrinogen
levels might have an association with an increased free flap
thrombosis incidence and could be considered as a genetic
marker associated with free flap thrombosis development
(Drizlionoka et al., 2019).
Interestingly, lower AT concentration does not inevitably
ensure thrombosis. In a study of a family with inherited AT
deficiency, there were few cases of pedigrees with low AT
plasma levels and with no convincing history of thrombosis
(van der Meer et al., 1973). We did not recognise a differ-
ence in plasma AT level either in patients carrying a het-
erozygous or homozygous form of SNP rs2227589 in the
SERPINC1 gene with or without free flap thrombosis. Both
patients with the heterozygous form of SNP and free flap
thrombosis had age under 50 years, which agrees with data
showing that the first thrombotic event usually occurs by
the age of 30 years and by the age of 50 years, and that 50%
of patients having AT deficiency will have had thrombosis
episode, generally DVT.
Seven out of the 12 analysed patients in the free flap throm-
bosis case series were carriers of the MTHFR gene
rs1801133 G/A genotype and had a higher serum homocys-
teine plasma level (> 12 mkmol/l). Two patients had solely
a mutation in the MTHFR gene. One eventually had free
flap thrombosis in arterial and the other in venous flow.
There have been controversies about whether an increase in
serum homocysteine levels is only associated with arterial
thrombosis, or also has an effect on VTE (Falcon et al.,
1994; Ray et al., 2002; Pathare et al., 2004). Thus, al-
though no general agreement has been reached, we support
the idea that a higher homocysteine plasma levels might be
associated with higher risk of free flap thrombosis, taking
into account that both arterial and venous blood flow are in-
volved.
There were few limitations in the study. The main limitation
was the rather small sample size; therefore, we were not
able to obtain strong findings by means of genotype inter-
group analysis. In the Centre of Plastic and Reconstructive
Microsurgery of Latvia about forty surgeries are performed
per year, limiting the sample size. Moreover, the analysed
clinical outcome in our study was free flap thrombosis. The
average incidence of free flap thrombosis varies between 8
and 10% (Vanags et al., 2020). In a recent study (Vanags et
al., 2020), free flap thrombosis developed in 15.5% of
microvascular flap surgery patients. It explains the rather
small sample size of patients with free flap thrombosis in
our study. Therefore, we were not able to find statistical sig-
nificant differences in coded plasma proteins and SNPs be-
tween those with and without free flap thrombosis, most
likely due to incomparable unequal sample size groups and
unequal distribution of genotype groups for each analysed
polymorphism.
Additionally, we were not able to assess the function of
coded plasma proteins related with analysed SNPs. Most
importantly for AT and fibrinogen, it would be advisable to
distinguish between qualitative or quantitative inherited
thrombophilia disorders. AT function in order to understand
whether patients are carrying SNP rather than I type AT de-
ficiency would be essential.
As reported previously (Vanags et al., 2020), although all
patients in our study received standardised treatment, and
received operations by experienced plastic surgeons who
routinely perform microvascular flap surgery, we consider
that technical surgical factors are one of most important
limitations. We were also not able to avoid the multifactor-
ial nature of a thrombotic event and the human factor in sur-
gery and post-operative care. Moreover, for patients that
had more than one SNPs, it was almost impossible to evalu-
ate the impact on one particular SNP in such a small study
population. Inherited thrombogenic factors and acquired
thrombogenic factors overlap, making it infeasible to distin-
guish the role of the SNP per se. Population bearing more
than one risk factor, either genetic or acquired, are at higher
risk and VTE is considered as a multigenetic/multifactorial
disease (Dahlbäck, 2005).
Finally, low incidence of rare allele SNPs and free flap
thrombosis rate revealed a rather wide confidence interval.
CONCLUSIONS
Our preliminary results showed that a lower aPCR level was
associated with FVL rs6025 C/T and higher fibrinogen
plasma levels with FGG rs2066865 A/A, suggesting that
these genotypes might predict higher free flap thrombosis
risk. However, we found no significant association between
the analysed SNPs and free flap thrombosis advancement.
We further aim to increase the study group to explore the
associations between the determined SNPs and free flap
thrombosis rate.
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IEDZIMTO TROMBOFÎLIJU LOMA TROMBOZES ATTÎSTÎBÂ MIKROVASKULÂRÂ LÇVERU ÍIRURÌIJÂ
Mikrovaskulârajâ íirurìijâ defektu slçgðanai no muskuïaudiem, kaulaudiem un/vai saistaudiem tiek veidots brîvais lçveris. Neraugoties uz
uzkrâtâm zinâðanâm, prasmçm un labu tehnisko nodroðinâjumu, brîvâ lçvera trombozçðanâs joprojâm ir aktuâla problçma. Lçveru
trombozçðanos, iespçjams, bûtiski varçtu ietekmçt iedzimtâs trombofîlijas, kuru loma ir aprakstîta citu tromboþu — kâ venozo, tâ
arteriâlo — attîstîbâ. Ðajâ prospektîvajâ pçtîjumâ mçs 152 pacientiem, kuriem veica mikrovaskulâro lçveru íirurìiju, noteicâm piecus
bieþâkos literatûrâ aprakstîtos polimorfismus: rs6025 FV Leidena (FVL) gçnâ, rs1799963 FII gçnâ, rs2066865 Fibrinogçna Gamma (FGG)
gçnâ, rs2227589 SERPINC1 gçnâ un rs1801133 MTHFR gçnâ, kâ arî novçrtçjâm ðo polimorfismu ietekmi uz to regulçto proteînu izmaiòâm
plazmâ. Dati tika vâkti laika posmâ no 2016. lîdz 2019. gadam Latvijas Mikroíirurìijas centrâ Rîgâ. Pirmie rezultâti uzrâdîja, ka pacientiem
ar C/T genotipu rs6025 FVL gçnâ ir ievçrojami zemâks rezistentâ aktivçtâ proteîna C (aPCR) lîmenis plazmâ, nekâ tiem ar C/C genotipu;
p = 0.006 (CI 95%, 0.44–1.1). Papildus novçrojâm, ka pacientiem ar A/A genotipu rs2066865 FGG gçnâ ir salîdzinoði augstâks fibrinogçna
lîmenis plazmâ (1.81 ± 5.6 g/l), nekâ tiem ar G/A un G/G genotipiem; p = 0.04 (CI 95%, 0.007–1.09); p = 0.004 (CI 95%, 0.48–2.49). Brîvâ
lçvera trombozi konstatçja 12 pacientiem (7.89 %). Tikai vienam no tiem varçja atrast sakarîbu starp brîvâ lçvera trombozçðanos un zemu
aPCR lîmeni plazmâ, pieòemot, ka lçvera trombozçðanos noteica mutâcija rs6025 FVL gçnâ. Secinâjums: kaut gan zemâks aPCR lîmenis
plazmâ korelçja ar C/T genotipu rs6025 FVL gçnâ un augstâks fibrinogçna lîmenis — ar A/A genotipu rs2066865 FGG gçnâ, kas varçtu
liecinât par augstâku trombozçðanâs risku, mçs neatradâm ticamu saistîbu starp noteikto gçnu polimorfismiem un brîvâ lçvera
trombozçðanos.
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